ArticlePharmaceutical research2026
Development of Sustained Release Chitosan/β-Glycerol Phosphate-Based Injectable Thermo-Gels Containing Naproxen Sodium: In-Vitro and In-Vivo Evaluation.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop in-situ chitosan/β-glycerol phosphate (β-GP) thermogels loaded with naproxen sodium for sustained drug delivery, to circumvent issues related with prolonged oral administration of naproxen (e.g. ulceration, abdominal discomfort, diarrhoea, bloating, etc.). To overcome these complications, in-situ gel formulations are developed as a promising strategy for long-term management of chronic inflammatory disorders such as arthritis. Furthermore, this system is evaluated with an earlier naproxen formulation prepared using sodium alginate.
methodsThermogels containing varying chitosan concentrations were prepared at pH 7.4 and 37°C, followed by drug loading. Key physicochemical properties, including injectability, gelation time, and sol-gel fraction, were evaluated. In-vitro release studies were conducted using a dialysis membrane with a USP dissolution basket apparatus-I. Anti-inflammatory efficacy was assessed in Sprague-Dawley rats with carrageenan-induced hind ankle inflammation.
resultsResults indicated that formulations with higher polymer content exhibited shorter gelation times and increased gel fractions. In-vitro release from F6CGP demonstrated sustained naproxen sodium delivery, following the Korsmeyer-Peppas model with Fickian diffusion kinetics (n ≤ 0.45). In-vivo, the swelling of the inflamed hind ankle joint decreased progressively over 72 h (≈ -2.6 ± 0.73 mm), confirming effective anti-inflammatory action; relatively better as compared to the previous sodium alginate system.
conclusionsIn-situ chitosan/β-glycerol gel-forming injectable formulation F6CGP provides sustained naproxen sodium release and shows potential as a therapeutic strategy for chronic inflammatory conditions such as arthritis. The results also indicate that this polymeric system can play a key role in modulating critical formulation parameters i.e. gelation time, gel fraction, injectability, drug release etc.
Indexed as
Identifiers
42773384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.